# Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy

> **NCT00142974** · PHASE2 · TERMINATED · sponsor: **Novartis** · enrollment: 120 (—)

## Conditions studied

- Diabetic Gastropathy

## Interventions

- **DRUG:** Tegaserod

## Key facts

- **NCT ID:** NCT00142974
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-05
- **Primary completion:** 2005-04
- **Final completion:** 2005-04
- **Target enrollment:** 120 (—)
- **Why stopped:** This study was terminated early in April 2005 due to low patient enrollment
- **Last updated:** 2012-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00142974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00142974, "Assessment of the Effect of Tegaserod (2 mg Tid and 6 mg Tid) on Dyspeptic Symptoms in Diabetic Patients With Symptoms of Diabetic Gastropathy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00142974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*